Boston Scientific (NYSE: BSX) has agreed to purchase EndoChoice Holdings Inc. (NYSE:GI), a developer of products that treat stomach and intestine illnesses, for approximately $210 million. Boston Scientific expects the deal will help expand the company “into new categories in the endoscopy market.”
Atlanta, Georgia-based EndoChoice provides pathology services, manufactures endoscopic imaging devices, and makes infection control products for specialists treating gastrointestinal conditions including colon cancer. For the 12 months ended June 2016, EndoChoice generated nearly $75 million in total sales. EndoChoice will join the buyer’s endoscopy business.